Summary of COVID-19 dalcetrapib studies

1. Kallend et al., A Double-blind, Placebo-controlled, Phase 2a Proof-of-concept Trial of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19

227 patient dalcetrapib early treatment RCT: 134% higher mortality (p=1), 134% higher ventilation (p=1), 139% higher need for oxygen therapy (p=0.68), and 37% higher hospitalization (p=1).
RCT 227 COVID-19 outpatients with symptom onset within 5 days, showing no signficiant benefits with dalcetrapib treatment.
May 2021, NCT04676867, https://clinicaltrials.gov/study/NCT04676867, https://c19p.org/kallend